Vajihe Akbari

Abstract The 10–23 DNAzyme is a versatile platform for programmable RNA cleavage in gene regulation and diagnostics; however, its practical efficacy remains limited by the absence of precise selection criteria for optimal enzyme–substrate pairs. While machine learning (ML) offers a robust framework for addressing this complexity, previous computational approaches have lacked sufficient predictive power and generalizability.

Abstract Immunotherapy with a combination of anti-CTLA-4 and anti-PD-1 antibodies has exhibited promising results for the treatment of many kinds of cancers in clinical practice. In the present study, we developed a novel bispecific daibody for simultaneous targeting of PD-1 and CTLA-4 to induce antitumor immunity. The bispecific single-chain diabody was designed on the basis of the amino acid sequences of variable regions of anti-PD1 and anti-CTLA4 antibodies.

Back to Journals » Breast Cancer: Targets and Therapy » Volume 18 Authors Abbaspour M, Esmaeil N , Akbari V , Ghoreishi M, Rafiepoor H Received 11 December 2025 Accepted for publication 29 April 2026 Published 5 May 2026 Volume 2026:18 588323 DOI https://doi.org/10.2147/BCTT.S588323 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Pooja Advani Maryam Abbaspour,1 Nafiseh Esmaeil,2 Vajihe Akbari,1 Mohammad Ghoreishi,1...